NCT07111351 Multi-omics Studies of Primary Aldosteronism
| NCT ID | NCT07111351 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Primary Aldosteronism |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-08-15 |
| Primary Completion | 2029-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-08-15 with a primary completion date of 2029-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary aldosteronism is a prevalent yet underdiagnosed cause of secondary hypertension, contributing to significant cardiovascular morbidity and renal dysfunction. Despite affecting up to 20% of hypertensive patients, PA is frequently missed because it lacks distinctive clinical features and often presents with nonspecific symptoms like resistant hypertension or subtle electrolyte imbalances. The diagnostic pathway involves a stepwise approach: initial screening via the aldosterone-to-renin ratio, confirmatory testing (e.g., saline suppression or captopril challenge), and subtype differentiation using adrenal venous sampling to distinguish unilateral adenoma from bilateral hyperplasia. This complexity, combined with clinician unfamiliarity and variable access to specialized centers, perpetuates underdiagnosis. Early identification and tailored treatment are paramount in improving outcomes for patients with primary aldosteronism. In this study, we will conduct a comprehensive multi-omics analysis on three sample types: 1) blood and urine samples from patients with primary aldosteronism, primary hypertension, and healthy controls; and 2) adrenal tissue samples from patients undergoing adrenalectomy for aldosterone-producing adenomas. We aim to systematically identify differentially expressed biomarkers that could serve as potential early diagnostic markers for primary aldosteronism. The findings may provide new insights into disease pathogenesis and contribute to improving early detection and personalized treatment strategies for this condition.
Eligibility Criteria
Inclusion Criteria: 1. Diagnosed with primary aldosteronism , primary hypertension , or age- and sex-matched healthy controls; 2. Aged 18-80 years with complete medical records; 3. Willing to participate voluntarily and provide informed consent. Exclusion Criteria: 1. History of chemotherapy or radiotherapy in the adrenal region ; 2. Positive serological or nucleic acid test results for HIV, hepatitis B, or hepatitis C , or a prior confirmed diagnosis; 3. Individuals with malignancies or autoimmune disorders ; 4. Study withdrawal during the trial period
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07111351 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07111351 currently recruiting?
Yes, NCT07111351 is actively recruiting participants. Contact the research team at hanwencong163@163.com for enrollment information.
Where is the NCT07111351 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07111351 clinical trial?
NCT07111351 is sponsored by Peking University First Hospital. The trial plans to enroll 400 participants.